INmune Bio completes first commercial manufacturing run of CORDStrom

INmune Bio (INMB) announced the successful completion of its first full-scale pilot commercial manufacturing run of CORDStrom, an off-the-shelf, allogeneic, umbilical cord tissue-derived mesenchymal stromal cell therapy for the treatment of Recessive Dystrophic Epidermolysis Bullosa. This milestone, achieved at the Cell and Gene Therapy Catapult’s state-of-the-art Manufacturing Innovation Centre in Stevenage, United Kingdom, marks a critical step toward regulatory submissions and keeps the Company on track for filing a Marketing Authorization Application in the UK during the first half of 2026 followed by a Biologics License Application in the US.